Condition: Metastatic Malignant Neoplasm in the Liver · Pancreatic Neuroendocrine Tumor · Stage I Pancreatic Neuroendocrine Tumor AJCC v8 · Sponsor: SWOG Cancer Research Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | Recruiting |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | Suspended |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | Recruiting |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | Recruiting |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | Suspended |
| Katmai Oncology Group | Anchorage, Alaska, United States | Recruiting |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | Recruiting |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | Active Not Recruiting |
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | Recruiting |
+ 436 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05040360